Ionis Pharmaceuticals (IONS) Income from Non-Controlling Interests (2009 - 2021)

Ionis Pharmaceuticals' Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at $500000.0 for Q4 2021.

• In Q4 2021, Income from Non-Controlling Interests rose 143.29% year-over-year to $500000.0; the TTM figure through Dec 2021 stood at $500000.0 (up 101.41% YoY), while the FY2025 annual figure was $100000.0, changed 0.0% from the prior year.
• Income from Non-Controlling Interests for Q4 2021 stood at $500000.0, up from -$1.2 million in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $19.5 million in Q4 2019, with the low at -$17.3 million in Q4 2018.
• The 5-year median for Income from Non-Controlling Interests is -$9.1 million (2019), against an average of -$6.4 million.
• The sharpest annual moves came in 2019 and 2020: Income from Non-Controlling Interests surged 212.67% in 2019, then tumbled 259.2% in 2020.
• Ionis Pharmaceuticals' Income from Non-Controlling Interests stood at -$6.2 million in 2017, then plunged by 177.64% to -$17.3 million in 2018, then soared by 212.67% to $19.5 million in 2019, then slumped by 105.91% to -$1.2 million in 2020, then surged by 143.29% to $500000.0 in 2021.
• Business Quant data shows IONS's Income from Non-Controlling Interests at $500000.0 in Q4 2021, -$1.2 million in Q4 2020, and -$12.1 million in Q3 2020.